YOLFTbeta
Q linea AB

Q linea AB

QLINEA · ST · Healthcare / Medical Devices

13.20SEK-0.05 (-0.38%)

Price History

Full chart

Market Stats

Previous Close13.25
Open13.25
Day Range13.00 – 13.30
52-Week Range14.55 – 38.43
Volume1.52K
Market Cap322.13M
P/E (TTM)0.00
Forward P/E0.00
EPS-13.20
Dividend Yield0.00%
Beta0.59
50-Day Avg18.18
200-Day Avg20.57

About

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Stuart Gander
  • Employees70
  • HeadquartersDag Hammarskjölds väg 52 A, Uppsala, Sweden, 752 37, Sweden
  • Websitehttps://qlinea.com

Leadership

  • Mr. Stuart GanderMD, President & CEO · b. 1978
  • Ms. Annika Blondeau HenrikssonCFO & IR · b. 1969
  • Mr. Henrik JacobsonChief Operating Officer · b. 1969
  • Ms. Natalie BrownDirector of Global Marketing · b. 1986
  • Ms. Ulrika StolpeHR Manager · b. 1967
  • Mr. Anders LjunggrenMD & Deputy CEO · b. 1981
  • Ms. Victoria LernerydManager of QA/RA · b. 1984

Financials

Income Statement

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue81.00K1.50M1.07M1.00M243.00K9.34M12.79M4.44M2.36M11.10M
Growth (%)-+1751.85%-28.93%-5.72%-75.82%+3741.56%+36.99%-65.28%-46.80%+369.86%
Cost of Revenue6.89M10.61M21.05M28.86M32.26M34.36M34.17M3.44M13.47M191.12M
Gross Profit-6.81M-9.11M-19.99M-27.85M-32.02M-25.03M-21.38M995.00K-11.11M-180.02M
Gross Margin-8403.70%-607.33%-1875.05%-2771.44%-13176.95%-268.12%-167.19%22.41%-470.49%-1622.09%
Operating Expense53.28M58.76M107.38M151.26M189.52M208.52M240.87M231.58M202.53M0
Operating Income-60.09M-67.87M-127.37M-179.12M-221.54M-233.55M-262.25M-230.59M-213.64M-180.02M
Operating Margin-74179.01%-4524.60%-11948.03%-17822.39%-91169.96%-2501.87%-2050.73%-5193.40%-9044.92%-1622.09%
EBITDA-58.44M-66.16M-124.31M-172.52M-211.02M-218.48M-252.69M-210.99M-195.40M-160.54M
EBITDA Margin-72150.62%-4410.53%-11661.73%-17166.27%-86838.68%-2340.42%-1975.99%-4751.94%-8272.73%-1446.54%
Net Income-60.09M-67.88M-128.35M-178.06M-220.19M-233.18M-275.77M-229.37M-216.87M-182.49M
Net Income Margin-74186.42%-4525.27%-12040.62%-17717.41%-90613.58%-2497.94%-2156.47%-5165.90%-9181.67%-1644.31%
R&D-53.66M98.13M121.69M156.39M156.95M151.97M128.09M--
R&D as % of Total Revenue-3577.00%9205.25%12108.06%64356.79%1681.27%1188.36%2884.95%--
Interest Expense7.00K24.00K1.00M706.00K1.54M769.00K719.00K1.57M3.71M6.79M
Interest Expense % of Total Revenue8.64%1.60%94.00%70.25%632.10%8.24%5.62%35.34%156.90%61.14%

Balance Sheet

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.96M16.86M18.40M539.07M374.41M412.23M466.63M207.39M231.98M147.99M369.67M
Total Liabilities5.55M8.41M16.89M25.61M33.46M32.03M35.84M45.76M42.34M175.45M31.66M
Total Equity8.41M8.45M1.51M513.46M340.94M380.20M430.79M161.63M189.64M-27.46M338.00M
Cash1.32M7.25M6.59M354.44M25.97M10.14M15.09M72.62M81.89M25.66M258.11M
Total Debt213.00K-3.00M1.13M709.00K331.00K13.31M20.93M20.56M151.21M5.84M
Net Debt-1.11M-7.25M-3.59M-353.31M-25.26M-9.81M-15.01M-51.69M-61.33M125.54M-252.26M

Cash Flow

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-52.83M-62.87M-122.71M-169.76M-237.31M-255.05M-250.86M-228.52M-182.50M-162.12M
Investing Cash Flow-1.02M-800.00K-164.25M-159.83M-32.30M-23.82M315.25M-7.77M-5.04M-7.22M
Financing Cash Flow59.79M63.00M634.81M1.12M253.78M283.81M-6.60M245.41M131.27M402.12M
Capital Expenditure1.02M938.00K1.40M7.63M13.23M11.97M17.25M8.34M4.99M7.56M
Free Cash Flow-53.85M-63.80M-124.11M-177.39M-250.53M-267.02M-268.11M-236.86M-187.49M-169.68M
Dividends Paid---1.12M------
FCF to OCF101.93%101.49%101.14%104.50%105.57%104.69%106.88%103.65%102.73%104.66%
Dividend Paid to FCF----0.63%------

Earnings

Report DateFeb 14, 2019May 3, 2019Jul 18, 2019Nov 7, 2019Feb 13, 2020May 7, 2020Jul 16, 2020Nov 5, 2020Feb 18, 2021May 6, 2021Jul 15, 2021Nov 4, 2021Feb 17, 2022May 5, 2022Jul 14, 2022Oct 31, 2022Feb 16, 2023May 4, 2023Jul 13, 2023Nov 2, 2023Feb 27, 2024May 31, 2024Jul 11, 2024Nov 5, 2024Feb 28, 2025Apr 14, 2025Jul 10, 2025Oct 30, 2025Feb 5, 2026Apr 13, 2026Jul 10, 2026
EPS Estimate---------------2.20-1.90-1.80-2.05-2.60-500.00-400.00-0.40-400.00-400.00-300.00------
EPS Actual-2.33-1.59-1.92-1.53-2.71-2.43-2.37-1.80-2.10-2.34-2.47-1.68-1.75-2.64-2.53-2.03-2.18-2.10-2.23-560.00-820.00-0.48-560.00-360.00-450.00-0.02-9.13-6.12-3.73-1.77-1.58
Surprise---------------15.00%-6.84%-21.11%-2.44%14.23%-12.00%-105.00%-20.00%-40.00%10.00%-50.00%------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap322.13M
Enterprise Value165.98M
Trailing P/E0.00
Forward P/E0.00
Price / Sales22.30
Price / Book1.24
EPS-13.20
Book Value14.50
Revenue (TTM)14.45M
Gross Profit (TTM)7.23M
EBITDA-137.81M
Profit Margin0.00%
Operating Margin-820.16%
Return on Equity-75.50%
Return on Assets-36.96%
Shares Outstanding18.95M
Shares Float11.64M
Beta0.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 22, 2025347:324
  • Jul 14, 20251:1000
  • Jan 13, 20252297:325